Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

Abstract

Even after gross tumor resection and combined radiochemotherapy, glioblastomas recur within a few months. Salvage therapy often consists of rechallenging with temozolomide in a dose-intensified schedule. Previously, low-dose metronomic temozolomide in combination with cyclo-oxigenase 2 inhibitors has had a beneficial effect as first-line treatment for glioblastoma. We report our experience with this procedure in recurrent glioblastomas after standard treatment. From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m(2) twice daily and 200 mg celecoxib. Before therapy the recurrent tumor was resected in 19 of 28 patients. Microvessel density (MVD) was determined by immunohistochemistry in 19 patients, and MGMT promoter methylation status, using the pyrosequencing method, was determined in 17 patients. In 14/28 patients, positron emission tomography with [F-18]-fluoroethyl)-L-tyrosine (FET-PET) was performed. Tumor progression was defined by the Macdonald criteria on MRI every 8-12 weeks or by clinical deterioration. The median time to progression was 4.2 months. Progression-free survival (PFS) after 6 months was 43%. Except for a lymphopenia in one patient, there was no grade 3 or 4 toxicity. PFS did not correlate with MVD or MGMT status. A high FET uptake correlated with tumor control after 6 months under therapy (P = 0.041, t-test). Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity. High FET uptake correlated with a better outcome under metronomic therapy.

• Authors: Florian Stockhammer, Martin Misch, Arend Koch, Marcus Czabanka, Michail Plotkin, Cristiane Blechschmidt, Jochen Tuettenberg, Peter Vajkoczy
• Journal: Journal of neuro-oncology (J Neurooncol) Vol. 100 Issue 3 Pg. 407-15 (Dec 2010) ISSN: 1573-7373 [Electronic] United States
• PMID: 20446016 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Cyclooxygenase 2 Inhibitors
• Fluorine Radioisotopes
• O-(3-fluoropropyl)tyrosine
• Pyrazoles
• Sulfonamides
• Tumor Suppressor Proteins
• Tyrosine
• Dacarbazine
• DNA Modification Methylases
• MGMT protein, human
• DNA Repair Enzymes
• Celecoxib
• Temozolomide

Topics

• Adult
• Aged
• Antineoplastic Agents, Alkylating (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols
• Brain Neoplasms (diagnostic imaging, drug therapy)
• Celecoxib
• Cyclooxygenase 2 Inhibitors (therapeutic use)
• DNA Modification Methylases (genetics, metabolism)
• DNA Repair Enzymes (genetics, metabolism)
• Dacarbazine (analogs & derivatives, therapeutic use)
• Disease-Free Survival
• Female
• Fluorine Radioisotopes
• Follow-Up Studies
• Glioblastoma (diagnostic imaging, drug therapy, physiopathology)
• Humans
• Male
• Methylation (drug effects)
• Middle Aged
• Positron-Emission Tomography (methods)
• Pyrazoles (therapeutic use)
• Retrospective Studies
• Sulfonamides (therapeutic use)
• Temozolomide
• Tumor Suppressor Proteins (genetics, metabolism)
• Tyrosine (analogs & derivatives)